Genome-editing technology has broad potential for treating cancers
the ONA take:
Researchers from the Walter and Eliza Hall Institute, in Melbourne, Australia, have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
Using the technology, called CRISPR, the researchers were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.
The technology can directly target any gene in a person’s genome, thereby overcoming many problems commonly encountered in drug development.
The system works by efficiently locating and targeting a particular gene. It can introduce mutations that make the genome nonfunctional, or introduce changes that make mutated genes function normally again.
The researchers report that the technology has a wide range of potential in terms of drug development for treating genetic diseases such as cancer.
Researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|